Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY09004 vs Eylea in wet AMD
CTR20202134Phase 3Completed
- Sponsor
- Boan Biotech
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in exudative macular degeneration, sponsored by Boan Biotech. Started Nov 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20202134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202134.